| Albireo–Ipsen: investment, 202301– cash tender offer $952m at $42/share plus 1 CVR/share entitling to $10/CVR |
2023-01-09 |
| Evosep–Novo Group: investment, 202301 minority investment of $40m by Novo Holdings A/S |
2023-01-09 |
| Affibody–EU (govt): credit, 202212– venture debt loan facility €20m from EIB supported by InvestEU programme |
2022-12-22 |
| Minervax–Adjuvant Capital: investment, 202212 financing round totalling €22m incl exisiting + co-investor Adjuvant Capital |
2022-12-15 |
| Minervax–Bellevue: investment, 202212 financing round totalling €22m incl new + co-lead investor Pureos Bioventures |
2022-12-15 |
| Minervax–EU (govt): credit, 202212 loan facility €50m from EIB |
2022-12-15 |
| Minervax–LF Investment: investment, 202212 financing round totalling €22m incl exisiting + co-investor LF Investment |
2022-12-15 |
| Minervax–Novo Group: investment, 202212 financing round totalling €22m incl exisiting + co-investor Novo REPAIR Impact Fund |
2022-12-15 |
| Minervax–Sanofi: investment, 202212 financing round totalling €22m incl exisiting + co-investor Sanofi Ventures |
2022-12-15 |
| Minervax–SEVERAL: investment, 202212 financing round €22m co-led by Trill Impact Ventures + Pureos Bioventures |
2022-12-15 |
| Minervax–Sunstone Life Science: investment, 202212 financing round totalling €22m incl exisiting + co-investor Sunstone Life Science Ventures |
2022-12-15 |
| Minervax–Sweden (govt): investment, 202212 financing round totalling €22m incl exisiting + co-investor Industrifonden |
2022-12-15 |
| Minervax–Trill Impact: investment, 202212 financing round totalling €22m incl new + co-lead investor Trill Impact Ventures |
2022-12-15 |
| Minervax–Wellington Partners: investment, 202212 financing round totalling €22m incl exisiting + co-investor Wellington Partners |
2022-12-15 |
| Chr. Hansen–Novozymes: investment, 202212– merger acquisition valuing Chr Hansen at DKK660.55/share ANNOUNCED |
2022-12-12 |
| Bico–Sartorius: investment, 202212– directed share issue SEK487m (€45m) to existing investor Sartorius resulting 10.1% share + 8.5% of voting rights |
2022-12-08 |
| Sartorius–Bico: laboratory equipment, 202212– collab RnD 3D cell printing technologies + digital soluitons for cell line development workflows |
2022-12-08 |
| Sartorius–Bico: laboratory equipment, 202212– distribution of Bico products in APAC region by Sartorius |
2022-12-08 |
| Hemispherian–Meneldor: investment, 202211 financing round Series A1 first tranche totalling NOK30m ($2.9m) incl existing + lead investor Meneldor |
2022-11-24 |
| Hemispherian–SEVERAL: investment, 202211 financing round Series A1 first tranche of NOK30m ($2.9m) led by Meneldor |
2022-11-24 |
| Accession Therapeutics–SEVERAL: investment, 202211 2nd financing round £16.6m incl iGlobe Partners + Primavera Venture Partners + Birk Venture |
2022-11-21 |
| Sarcura–Axilium Holding: investment, 202211 seed plus financing round totalling €7m incl existing + co-investor Axilium Holding |
2022-11-17 |
| Sartorius–SEVERAL: credit, 202211– placement of total of €650m Schulschein loans with 3, 5, 7, 10 + 13 years maturity |
2022-11-11 |
| BC Platforms–Jolt Capital: investment, 202211 growth financing round totalling CHF20m incl new + lead investor Jolt Capital |
2022-11-08 |
| BC Platforms–SEVERAL: investment, 202211 growth financing round CHF20m led by new investor Jolt Capital |
2022-11-08 |
| Binding Site–Thermo Fisher: investment, 202210– acquisition £2.25b in cash from shareholder group led by Nordic Capital ANNOUNCED |
2022-10-31 |
| Univ Copenhagen–Resolve Biosciences: Molecular Cartography technology, 202210 supply to Novo Nordisk Foundation Center existent |
2022-10-24 |
| Hemispherian–EU (govt): grant, 202210– grant €2.5m from EIC Accelerator programme |
2022-10-19 |
| Hemispherian–EU (govt): investment, 202210– equity financing €7.5m from EIC Fund RECOMMENDED |
2022-10-19 |
| MS-Omics–Clinical Microbiomics: investment, 202210 acquisition of MS-Omics ApS by Clinical Microbiomics A/S |
2022-10-17 |
| Clinical Microbiomics–BPCE: investment, 202210 investment €10m from Health for Life Capital II fund managed by Seventure Partners |
2022-10-11 |
| Cevec–Danaher: investment, 202210 acquisition of Cevec by Cytiva |
2022-10-06 |
| Novo Group–Ventus Therapeutics: NLRP3 inhibitor, 202209– excl ww developm + license agreem $70m upfront + $633m milestones for lead program |
2022-09-29 |
| Novo Group–Microsoft: AI-based drug discovery, 202209 collab strategic combining MS computation services + cloud + AI with Novo RnD + data science |
2022-09-12 |
| Pretzel Therapeutics–SEVERAL: investment, 202209 financing round Series A $72.5m led by ARCH Venture Partners + Mubadal Capital |
2022-09-12 |
| Pretzel Therapeutics–Ten Bridge Communications: public relations, 202209 service existent Ten Bridge is media contact |
2022-09-12 |
| Onego Bio–Finland (govt): grant, 202209 grant €4.5m from Business Finland |
2022-09-07 |
| Forma Therapeutics–Novo Group: investment, 202209– acquisition $1.1b cash tender of by Novo Nordisk at $20/share |
2022-09-01 |
| eTheRNA–EQT: investment, 202208 financing round Series B2 totalling €39m incl existing + co-investor EQT Life Sciences (formerly LSP) |
2022-08-23 |
| eTheRNA–PERSON: investment, 202208 financing round Series B2 totalling €39m incl new + co-investor Kenneth Chien |
2022-08-23 |
| eTheRNA–SEVERAL: investment, 202208 financing round Series B2 €39m led by existing investor Novalis LifeSciences LLC |
2022-08-23 |
| Albumedix–Sartorius: investment, 202208–202209 acquisition £415m 100% of Albumedix by Sartorius Stedim Biotech |
2022-08-08 |
| Atlas Antibodies–Genovis: MS-based analysis of biopharmaceuticals, 202208– supply service LC-MS analytics of recombinant CHO-antibodies to Evitria |
2022-08-08 |
| Genmab–BioNTech: cancer immunotherapy, 202208– collab expansion 50/50 cost + profit sharing developm + commercn monospeific antibodies using HexaBody |
2022-08-05 |
| Active Biotech–SEVERAL: investment, 202208– rights issue up to SEK54.5m with up to 54.5m new shares at SEK1/share |
2022-08-04 |
| SHS Capital–Realdania: investment, 202207 first closing totalling over €220m of SHS VI fund incl investor Realdania Foundation |
2022-07-18 |
| SHS Capital–SEVERAL: investment, 202207 first closing at over €220m of SHS VI fund with EIF + Realdania + Helsana HealthInvest + LBBW et al. |
2022-07-18 |
| Navinci Diagnostics–Beijer Ventures: investment, 202207 financing round Series A totalling SEK90m incl existing + co-investor Beijer Ventures AB |
2022-07-12 |
| Navinci Diagnostics–Landegren Gene Technology: investment, 202207 financing round Series A totalling SEK90m incl existing + co-investor LGT |
2022-07-12 |
| Navinci Diagnostics–Nexttobe: investment, 202207 financing round Series A totalling SEK90m incl existing + co-investor Nexttobe AB |
2022-07-12 |
| Navinci Diagnostics–Segulah Medical Acceleration: investment, 202207 financing round Series A totalling SEK90m incl new + lead investor SMA |
2022-07-12 |
| Navinci Diagnostics–SEVERAL: investment, 202207 financing round Series A SEK90m led by new investor Segulah Medical Acceleration |
2022-07-12 |
| Biosyntia–ECBF: investment, 202207 financing round Series B totalling €11.5m incl new + lead investor ECBF |
2022-07-07 |
| Biosyntia–Novo Group: investment, 202207 financing round Series B totalling €11.5m incl existing + co-investor Novo Seeds |
2022-07-07 |
| Biosyntia–SEVERAL: investment, 202207 financing round Series B €11.5m led by new investor ECBF |
2022-07-07 |
| Biosyntia–Sofinnova: investment, 202207 financing round Series B totalling €11.5m incl existing + co-investor Sofinnova Partners |
2022-07-07 |
| BioPhero–FMC: investment, 202206– acquisition $200m at closing of BioPhero by FMC ANNOUNCED |
2022-06-29 |
| SPT Labtech–EQT: investment, 202206– acquisition £650m of SPT Labtech by EQT IX Fund from Battery Ventures |
2022-06-22 |
| CH-Bioforce–EU (govt): grant, 202206– EIC Accelerator programme grant up to €15m to advance biomass processing plant |
2022-06-21 |
| Elypta–Bonnier: investment, 202206 financing round Series A totalling $21m incl lead investor Bonnier Ventures |
2022-06-20 |
| Elypta–Chalmers Univ: investment, 202206 financing round Series A totalling $21m incl existing + co-investor Chalmers Ventures |
2022-06-20 |
| Elypta–Hillclimber: investment, 202206 financing round Series A totalling $21m incl existing + co-investor Hillclimber |
2022-06-20 |
| Elypta–Nina Capital: investment, 202206 financing round Series A totalling $21m incl existing + co-investor Nina Capital |
2022-06-20 |
| Elypta–Norrsken Foundation: investment, 202206 financing round Series A totalling $21m incl existing + co-investor Norrsken VC |
2022-06-20 |
| Elypta–SEVERAL: investment, 202206 financing round Series A $21m led by Bonnier Ventures |
2022-06-20 |
| Elypta–Sweden (govt): investment, 202206 financing round Series A totalling $21m incl existing + co-investor Industrifonden |
2022-06-20 |
| Elypta–Wallenberg: investment, 202206 financing round Series A totalling $21m incl existing + co-investor Navigare Ventures |
2022-06-20 |
| ImCheck Therapeutics–EQT: investment, 202206 financing round Series C totalling €80m incl existing + co-investor EQT Life Sciences |
2022-06-13 |
| Peptone–Nvidia: AI-based drug discovery, 202206 collab incl use of Nvidia DGX A100 supercomputer to run Peptone’s algorithmic engine |
2022-06-09 |
| Ariceum Therapeutics–Bellevue: investment, 202206 financing round Series A totalling €25m incl co-investor Pureos Bioventures |
2022-06-08 |
| Ariceum Therapeutics–EQT: investment, 202206 financing round Series A totalling €25m incl co-founding + co-lead investor EQT Life Sciences |
2022-06-08 |
| Ariceum Therapeutics–Odlander Fredrikson: investment, 202206 financing round Series A totalling €25m incl co-founding + co-lead investor HealthCap |
2022-06-08 |
| Ariceum Therapeutics–SEVERAL: investment, 202206 financing round Series A €25m co-led by HealthCap + EQT Life Sciences |
2022-06-08 |
| Synklino–Denmark (govt): investment, 202206 financing round Series A totallling €29.8m incl existing + co-investor Vaekstfonden |
2022-06-08 |
| Synklino–Eir Ventures: investment, 202206 financing round Series A totallling €29.8m incl existing + co-investor Eor Vemtures |
2022-06-08 |
| Synklino–Maj Invest: investment, 202206 financing round Series A totallling €29.8m incl new + co-investor Maj Invest |
2022-06-08 |
| Synklino–Optimum Strategic Communications: public relations, 202206 service existent by Optimum |
2022-06-08 |
| Synklino–PKA: investment, 202206 financing round Series A totallling €29.8m incl new + lead investor PKA Pension Fund |
2022-06-08 |
| Synklino–SEVERAL: investment, 202206 financing round Series A €29.8m (DKK222m) led by PKA Pension Fund |
2022-06-08 |
| Colorifix–SEVERAL: investment, 202205 financing round Series B £18m led by H&M CO:LAB |
2022-05-27 |
| Pancryos–Partners HealthCare: drug delivery technology, 202205– license ww excl from BWH for ceMED for delivery of PanINSULA |
2022-05-24 |
| Synexa Life Sciences–Gilde Investment: investment, 202205 existent Synexa is backed by Gilde Healthcare |
2022-05-19 |
| Syrinx Bioanalytics–Synexa Life Sciences: investment, 202205 acquisition of Syrinx Bioanalytics Oy by Synexa |
2022-05-19 |
| Artax Biopharma–SEVERAL: investment, 202205 financing round $26m with new investors Eli Lilly + Sound Bioventures et al |
2022-05-11 |
| Artax Biopharma–Sound Bioventures: investment, 202205 financing round totalling $26m incl new investor Sound Bioventures |
2022-05-11 |
| Allegro 3D–Bico: investment, 202205 acquisition of Allegro 3D for $6m upfront + $5m milestones in cash |
2022-05-05 |
| Sidekick Health–Asabys Partners: investment, 202205 financing round Series B totalling $55m incl co-investor Asabys Partners |
2022-05-05 |
| Sidekick Health–Frumtak Ventures: investment, 202205 financing round Series B totalling $55m incl co-investor Frumtak Ventures |
2022-05-05 |
| Sidekick Health–Novator Partners: investment, 202205 financing round Series B totalling $55m incl existing + lead investor Novator Ventures |
2022-05-05 |
| Sidekick Health–OTHER: investment, 202205 financing round Series B totalling $55m incl co-investor undisclosed US-based strategic investor |
2022-05-05 |
| Sidekick Health–SEVERAL: investment, 202205 financing round Series B $55m led by Novator Ventures |
2022-05-05 |
| Sidekick Health–Wellington Partners: investment, 202205 financing round Series B totalling $55m incl existing + co-investor Wellington Partners |
2022-05-05 |
| Engimmune Therapeutics–SEVERAL: investment, 202205 seed financing round CHF15.5m co-led by Pureos Bioventures + Novo Seeds |
2022-05-03 |
| Hemispherian–Meneldor: investment, 202205 seed financing round totalling NOK12.5m ($1.4m) incl lead investor Meneldor |
2022-05-03 |
| Hemispherian–SEVERAL: investment, 202205 seed financing round NOK12.5m ($1.4m) led by Meneldor with Norwegian + American investors |
2022-05-03 |
| Cinclus Pharma–SEVERAL: investment, 202204–202205 private placement SEK250m with Trill Impact + Eir Ventures I + Irrus Investments + AP4 + Linc |
2022-04-19 |
| Labster–Andreessen Horowitz: investment, 202204 financing round Series C 2nd tranche totalling $47m incl existing investor Andreessen Horowitz |
2022-04-04 |
| Labster–EduCapital: investment, 202204 financing round Series C 2nd tranche totalling $47m incl existing investor EduCapital |
2022-04-04 |
| Labster–GGV Capital: investment, 202204 financing round Series C 2nd tranche totalling $47m incl existing investor GGV Capital |
2022-04-04 |
| Labster–NPF Technologies: investment, 202204 financing round Series C 2nd tranche totalling $47m incl existing investor NPF Technologies |
2022-04-04 |
![[LSS] Life-Sciences-Scandinavia.com - The Scandinavian Life Sciences Web Portal](/images/basics/lss-life-sciences-scandinavia-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
